CagriSema vs Lipo-C Injection
A side-by-side research comparison of CagriSema and Lipo-C Injection across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | Lipo-C Injection |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | Lipotropic MIC + B12 Injection |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Compounded medication |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | Methionine provides sulfur for detoxification, inositol supports fat transport from liver, choline emulsifies cholesterol and fat, B12 boosts cellular energy metabolism and red blood cell production. |
| Molecular weight | Combination product | Combination compound |
| Half-life | 7 days (both components) | Variable by component |
| Bioavailability | High (SubQ) | ~100% IM injection |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | 1 mL |
| Frequency | Once weekly | 1-2x per week |
| Route | Subcutaneous | Intramuscular or subcutaneous injection |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Lipo-C Injection reported benefits
- Enhanced fat metabolism
- Liver support
- Increased energy
- B12 optimization
- Complements weight loss protocols
Related comparisons
Research and educational reference only. Not medical advice.